drugset / Trial / NCT01485952
An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients With SEN0014196
Phase 1
Completed
55 enrolled
Siena Biotech S.p.A.
European Huntington's Disease Network · collabSeventh Framework Programme · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of this study is to provide biological samples from patients with Huntington's disease to allow characterisation of the pharmacological mechanism of action of SEN0014196.
Timeline
- Start
- 2011-03
- Primary completion
- 2011-11
- Completion
- 2011-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SEN0014196 | Unknown | 10 mg | Oral |
| Subject | SEN0014196 | Unknown | 100 mg | Oral |